INTRODUCTION
============

Resistant hypertension (HTN) is defined as either the failure to achieve the target blood pressure (BP; \<140/90) with three antihypertensive drugs of different classes, including diuretics, or the achievement of BP by using four or more antihypertensive drugs.[@B1] It is associated with a significant elevation of cardiovascular risk.[@B2][@B3][@B4] Therefore, early recognition and rigorous management are necessary to reduce cardiovascular mortality.[@B5] The prevalence of resistant HTN has been reported to be as high as 30% in hypertensive patients.[@B4] There are many causes of resistant HTN, including high sodium-containing diets, alcohol, non-adherence to drug treatments, inadequate medications, obesity, and secondary HTN.[@B6] Among the causes of secondary HTN, obstructive sleep apnea (OSA) is strongly associated with resistant HTN.[@B7] Surprisingly, the prevalence of OSA in resistant hypertensive patients ranges from 64%[@B8] to 83%,[@B9] which is significantly higher than its prevalence (4%) in the general population.[@B10]

OSA is characterized by the partial or complete collapse of the upper airway during sleep, and it is diagnosed when the apnea-hypopnea index (AHI), as detected by polysomnography (PSG), is greater than 5. OSA affects 2-4% of adults and is associated with increased cardiovascular risks and mortality.[@B11] It is very common in hypertensive patients, and the prevalence has been reported to be as high as 56%.[@B12][@B13] Resistant HTN and OSA are commonly associated with various physiological conditions, such as hyperaldosteronism, increased sympathetic activity, endothelin- and hypoxia-mediated vasoconstriction, and obesity.[@B14] Furthermore, BP control is critical for reducing cardiovascular morbidity and mortality,[@B15] and the treatment of OSA with continuous positive airway pressure (CPAP) modestly diminishes BP in patients with various types of HTN,[@B16] including resistant HTN.[@B17] The modest effect of CPAP on BP reduction in resistant hypertensive patients suggests that the high prevalence of OSA in these patients may not entirely be explained by sleep apnea which exacerbates blood pressure elevation, but also be due to common associations with risk factors. Therefore, OSA and resistant HTN do not appear be causally related. In this study, we aimed to determine the clinical, laboratory, and polysomnographic features of resistant HTN that are significantly associated with OSA. Also, we determined the association of resistant HTN with OSA after controlling for risk factors that are related to both conditions.

MATERIALS AND METHODS
=====================

Study population
----------------

This retrospective study was approved by the Institutional Review Board (IRB) at Yonsei University College of Medicine (IRB No. 4-2014-0132). We enrolled hypertensive patients who visited the Cardiology Department at Yonsei University College of Medicine between 2010 and 2013 who completed the PSG procedure, sleep questionnaires, and basal blood tests. PSG was performed using Embletta X100 (Natus Embla Systems LLC, Ontario, Canada),[@B18] which is a type 2 full-unattended portable system by the American Academy of Sleep Medicine.[@B19] This type 2 portable monitor incorporates a minimum of seven channels, including two electroencephalography (EEG) channels. This allows for the AHI to be accurately calculated and is an improvement over the rough estimates that are obtained by type 3 or 4 portable systems.[@B20] The inter- \[95% confidence interval (CI), 0.993-0.999; *p*\<0.001\] and intra-class correlation coefficients (95% CI, 0.993-0.999; *p*\<0.001) for the inter-observer reliability of the AHI were checked. OSA was diagnosed when the AHI was greater than 5. Mild, moderate, and severe OSA were defined by indices of 5-14, 15-29, and \>30, respectively. BP was measured twice either with a mercury sphygmomanometer or an aneroid sphygmomanometer (Welch Allyn Silver Series DS45, Skaneateles Falls, NY, USA), and the average value was used.

Anthropometric measurements and metabolic assessments
-----------------------------------------------------

Anthropometric measurements were performed by a skilled examiner. Height was defined as the length from the top of the head to the end of the first toe. Neck circumference (NC) was measured at the thyroid cartilage level with a ruler. Waist circumference (WC) was measured at the midway point between the inferior costal margin and the superior border of the iliac crest. Hip circumference (HC) was measured at the largest lateral extension of the hips.

Blood samples were collected after overnight fasting, and the levels of total cholesterol, triglycerides (TG), high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, and blood glucose were measured.

Statistics
----------

Independent two-sample t-tests were used for the comparison of continuous variables. The stepwise multivariate logistic regression analysis was used to determine risk factors that were associated with OSA. Discrete variables were compared using the chi-square test. The criterion for entering or removing variables in the multivariate regression model was a *p*-value of 0.25. The variables that were initially entered in the stepwise analysis were chosen from the preliminary univariate analyses with *p*\<0.01. Statistical analyses were performed by SPSS version 20 (IBM Corporation, Armonk, NY, USA) and SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).

RESULTS
=======

Flowchart of patients
---------------------

This was a retrospective analysis of the sleep apnea registry of the Cardiology Department at Yonsei University. During a 3-year period, 948 hypertensive patients underwent PSG for the evaluation of secondary HTN and/or OSA-related symptoms. Among these subjects, 364 patients were excluded due to incomplete medical records, and 109 patients were excluded due to missing values in anthropometric measurements, laboratory tests, PSG data, or sleep questionnaires. Finally, 475 patients with complete data were enrolled in the study for analysis ([Fig. 1](#F1){ref-type="fig"}).

Medical history of controlled and resistant hypertensive patients
-----------------------------------------------------------------

The enrolled patients were identified as having controlled (n=410) or resistant HTN (n=65). We reviewed the anti-hypertensive medications that were used by patients and categorized them as diuretics, angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, calcium channel blockers, α- and β-receptor blockers, and vasodilators ([Table 1](#T1){ref-type="table"}). The average numbers of medications that were used by patients with controlled and resistant HTN were 2.01±0.98 and 4.27±0.95, respectively.

Severity of OSA in patients with controlled or resistant HTN
------------------------------------------------------------

OSA, which was characterized by an AHI≥5, was diagnosed in 73.7% (302/410) and 87.7% (57/65) of patients in the controlled and resistant HTN groups, respectively ([Table 2](#T2){ref-type="table"}, [Fig. 2A](#F2){ref-type="fig"}). Overall, 359 hypertensive patients (75.6%) were diagnosed with OSA ([Table 2](#T2){ref-type="table"}, [Fig. 2A](#F2){ref-type="fig"}). The prevalence of OSA in resistant hypertensive patients was significantly higher than that in controlled hypertensive patients (*p*=0.015) ([Fig. 2A](#F2){ref-type="fig"}). When we used the AHI to categorize the severity of OSA as mild, moderate, or severe, the resistant HTN group had a higher percentage of moderate (35.4% vs. 23.2%) and severe (26.1% vs. 19.5%) OSA patients, compared to the controlled HTN group ([Fig. 2B and C](#F2){ref-type="fig"}).

Anthropometric characteristics, PSG, and basal laboratory results in patients with controlled or resistant HTN
--------------------------------------------------------------------------------------------------------------

We evaluated the differences in anthropometric, polysomnographic, and basal laboratory features between controlled and resistant hypertensive patients ([Table 3](#T3){ref-type="table"}). Body weights, body mass index (BMI), NC, WC, and HC were significantly higher in the resistant HTN group, compared with the controlled HTN group (*p*\<0.05). Based on the independent two-sample t-test, the AHI was also significantly higher in the resistant HTN group than in the controlled HTN group (*p*\<0.05). In addition, resistant hypertensive patients had significantly worse values for polysomnographic parameters, such as average O~2~ saturation, lowest O~2~ saturation, and O~2~ desaturation index. No differences in the longest duration of apnea or hypopnea and average heart rate were observed between groups. Interestingly, TG levels were higher in patients with resistant HTN (*p*=0.050); however, there were no significant differences in the levels of glucose, total cholesterol, HDL-cholesterol, and LDL-cholesterol between groups ([Table 3](#T3){ref-type="table"}).

Anthropometric characteristics and basal laboratory results in OSA and non-OSA hypertensive patients
----------------------------------------------------------------------------------------------------

To determine the common variables that are associated with both OSA and resistant HTN, we regrouped all hypertensive patients into non-OSA (n=114) and OSA (n=361) groups. The patients who had OSA were significantly older (55.89±12.46 years old) than non-OSA (48.72±13.74 years old) patients (*p*\<0.001). Anthropometric characteristics, such as body weight, BMI, NC, WC, and HC, were also significantly higher in the OSA group than in the non-OSA group. In addition, decreased HDL-cholesterol levels were observed in the OSA group (*p*\<0.05) ([Table 4](#T4){ref-type="table"}).

The association of resistant HTN with OSA
-----------------------------------------

Using the stepwise logistic regression analysis, waist (chisquare= 28.82, *p*\<0.001), age (chi-square=35.01, *p*\<0.001), gender (chi-square=16.02, *p*\<0.001), and NC (chi-square=3.39, *p*=0.066) were significantly associated with OSA. However, resistant HTN was not significantly associated with OSA in the multivariate logistic regression analysis (chi-square=1.62, *p*=0.203) ([Table 5](#T5){ref-type="table"}).

DISCUSSION
==========

The prevalence of OSA is reported to be between 2% and 7% in middle-aged adult populations, but the prevalence of OSA without symptoms has been reported to be up to 20%.[@B21] In patients with cardiovascular disease, the prevalence of OSA has been shown to be as high as 60%,[@B22] and approximately 80% of resistant hypertensive patients have OSA.[@B8][@B9] Although previous studies have shown that the risk for OSA is significantly increased in subjects with resistant HTN compared to those with controlled HTN,[@B23] population studies regarding the association between resistant HTN and OSA are limited. Because resistant HTN and OSA share common risk factors, including age and obesity,[@B1][@B24] we sought to determine whether resistant HTN is an independent risk factor for OSA. We also examined whether resistant HTN and OSA are causally related.

First, we compared various clinical characteristics, such as body weight, BMI, NC, WC, and HC, between controlled and resistant hypertensive patients. The results showed that these clinical features were higher in resistant HTN patients. These parameters were also significantly associated with OSA in the entire study population ([Table 4](#T4){ref-type="table"}). One important risk factor for OSA is obesity, as 40% of obese subjects have OSA.[@B25] Furthermore, a 10% increase in body weight contributes to a 6-fold increase in the odds of developing OSA.[@B26] Therefore, we suspected that these propensities for obesity might be responsible for the higher prevalence of OSA in patients with resistant HTN. This hypothesis was based on the fact that CPAP only modestly reduces BP in OSA patients. In the open-randomized HIPARCO study, which assessed the effect of CPAP in patients with resistant HTN, there was a small but significant decrease in mean BP over a 24-hour period.[@B27] Through a meta-analysis of 16 randomized clinical trials, Bazzano, et al.[@B28] concluded that effective CPAP treatment reduces BP, but its mean effect is modest at best. Although there are various differences in the duration of treatment, CPAP adherence, study design, and cohort size of these clinical trials, the modest effect of CPAP suggests that OSA may be a partial contributing factor to the pathophysiological mechanism of resistant HTN development. In addition, Friedman, et al.[@B29] have demonstrated that the association between OSA and resistant HTN may be due to exaggerated fluid volume displacement from the legs to the upper airways. However, this is not supported clinically, because β-blockers, rather than diuretics, are more effective in reducing BP in hypertensive subjects with OSA.

OSA is characterized by repetitive pharyngeal narrowing during sleep. This is due to the deposition of fat in the upper airway[@B30] and the redistribution of intravascular and interstitial fluid in the pharyngeal structure. The hypothesis of rostral fluid shift from the legs into the neck is a potential mechanism for the aggravation of OSA, and it is well established in non-obese patients.[@B31] However, Jafari and Mohsenin[@B32] showed that fluid shift does not significantly change the respiratory disturbance index, which is a sum of the AHI and respiratory effort-related arousal, and it does not worsen the severity of OSA.

Results from our stepwise logistic regression analyses showed that resistant HTN itself was not significantly associated with OSA, after controlling for age and indices of obesity, compared to total HTN patients ([Table 5](#T5){ref-type="table"}). Although resistant HTN was significantly associated with the presence of OSA in univariate analysis ([Table 4](#T4){ref-type="table"}), the association became non-significant when the obesity factors were adjusted by stepwise and multivariate analyses and controlled HTN was compensated ([Table 5](#T5){ref-type="table"}). In addition, the results in [Table 3](#T3){ref-type="table"} showed that resistant HTN had more obesity than controlled HTN. Similar to our finding, it has been reported that weight loss combined with CPAP was effective for the control of blood pressure.[@B33] Taken together, these findings suggest that the high prevalence of OSA in resistant hypertensive patients is due to the sharing of common risk factors ([Table 3](#T3){ref-type="table"} and [5](#T5){ref-type="table"}). Furthermore, the correction of clinical risk factors should not be overlooked in the management of resistant hypertensive patients. In particular, obesity should be emphasized for both OSA and resistant HTN. Therefore, both weight loss and CPAP usage are necessary for BP control in overweight patients with concurrent resistant HTN and OSA.

Another risk factor for the pathogenesis of cardiovascular disease, including resistant HTN, is metabolic syndrome. Importantly, it is highly associated with OSA.[@B34] Results from multivariate analyses show that the presence of OSA was significantly associated with metabolic syndrome in all hypertensive groups (OR=2.529, *p*\<0.001) ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}, only online). Although the high prevalence of metabolic syndrome may be due to common sharing of risk factors, such as obesity, OSA itself can enhance insulin resistance by increasing sympathetic nervous system activation and elevating systemic inflammation.[@B34] This is supported by the fact that CPAP usage is associated with an improvement in lipid profiles, glycosylated hemoglobin levels, and BP.[@B35]

Our study has several limitations. First, this was a retrospective analysis of registry data with cross-sectional analysis. Second, we did not have full data regarding the etiologies of secondary HTN in the resistant HTN group. Third, portable PSG was used instead of fully attended in-laboratory PSG, which is typically used in the diagnosis of OSA. However, our device is a type 2 portable monitor with EEG channels, which enables the AHI to be accurately calculated, and this was manually scored by sleep technologists and validated by a sleep expert. Portable PSG is effective and may be used as an alternative to in-laboratory PSG, especially in patients with a high clinical probability of OSA.[@B36][@B37][@B38] Fourth, we did not exclude subjects with white-coat hypertension. Lastly, as we utilized hospital-based registry data, the results from the study cannot be generalized to the general population. Nevertheless, the ability to analyze the association between resistant HTN and OSA in a relatively large registry is a merit of this study.

We evaluated various clinical and polysomnographic characteristics in controlled and resistant hypertensive patients who were suspected to have OSA, and found that the prevalence of OSA was higher and more severe in patients with resistant HTN than those with controlled HTN. Our results from univariate and stepwise logistic analyses showed that resistant HTN was not an independent risk factor for OSA, and that the high prevalence of OSA in resistant HTN was due to the sharing of common risk factors for both conditions.
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###### Supplementary Fig. 1

The relationship between OSA and metabolic syndrome in patients with controlled or resistant HTN. The number of patients with or without metabolic syndrome was compared among patients with resistant, controlled, and total hypertension. Each odds ratio (OR) was calculated. Metabolic syndrome was significantly associated with OSA in the controlled and total hypertensive groups (^\*^*p*\<0.01). OSA, obstructive sleep apnea; HTN, hypertension.

![Flowchart of patients. Hypertensive patients were asked to perform the sleep study (including polysomnography, sleep questionnaires, laboratory tests, and anthropometric measurements), and 475 patients with complete data were enrolled in this retrospective study.](ymj-56-1258-g001){#F1}

![Severity of OSA in HTN. The apnea-hypopnea index (AHI) was used to determine the prevalence and severity of OSA in controlled and resistant hypertensive patients. (A) The prevalence of OSA in controlled, resistant, and total hypertensive patients was compared. (B) The average AHIs of non-OSA, mild, moderate, and severe degrees of OSA are represented as mean±standard deviation in the controlled and resistant HTN groups. (C) The percentages of patients with non-OSA, mild, moderate, and severe OSA were compared between the controlled and resistant HTN groups (^\*^*p*\<0.05). OSA, obstructive sleep apnea; HTN, hypertension.](ymj-56-1258-g002){#F2}

###### Review of Enrolled Patients\' Blood Pressure Medications

![](ymj-56-1258-i001)

                          Controlled HTN (n=410)   Resistant HTN (n=65)
  ----------------------- ------------------------ ----------------------
  Number of medications   2.01±0.98                4.27±0.95
  Diuretics (%)           32                       86
  ACEI (%)                7                        14
  ARB (%)                 61                       77
  CCB (%)                 56                       89
  α-blocker (%)           1                        29
  β-blocker (%)           30                       78
  Vasodilator (%)         11                       31

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; CCB, calcium channel blocker; HTN, hypertension.

###### Severity of OSA Based on the AHI in Patients with Controlled or Resistant HTN

![](ymj-56-1258-i002)

                       Controlled HTN (n=410)   Resistant HTN (n=65)   Total (n=475)                       
  -------------------- ------------------------ ---------------------- --------------- ----------- ------- ------------
  Non-OSA (0-4.9)      2.10                     108 (26.3)             2.87            8 (12.3)    2.15    116 (24.4)
  Mild (5-14.9)        9.55                     127 (31.0)             9.17            17 (26.2)   9.50    144 (30.4)
  Moderate (15-29.9)   20.94                    95 (23.2)              20.67           23 (35.4)   20.88   118 (24.8)
  Severe (30+)         45.63                    80 (19.5)              49              17 (26.1)   46.21   97 (20.4)
  Total                17.26                    410 (100)              22.87           65 (100)    18.03   475 (100)

HTN, hypertension; AHI, apnea-hypopnea index; OSA, obstructive sleep apnea.

###### Anthropometric Characteristics, Polysomnography, and Basal Laboratory Results in Patients with Controlled or Resistant HTN

![](ymj-56-1258-i003)

                                          Controlled HTN (n=410)   Resistant HTN (n=65)   *p* value
  --------------------------------------- ------------------------ ---------------------- -----------
  Age (yrs)                               54.33±12.85              53.15±14.83            0.500
  Sex, male:female (percentage of male)   303:107 (73.9%)          47:18 (72.3%)          0.786
  Height (cm)                             166.94±8.47              167.84±7.33            0.417
  Weight (kg)                             73.30±11.94              79.96±16.05            \<0.001
  BMI (kg/m^2^)                           26.10±3.27               28.05±4.18             \<0.001
  Neck circumference (cm)                 38.11±3.20               39.98±3.75             \<0.001
  Waist circumference (cm)                93.05±8.93               99.12±9.28             \<0.001
  Hip circumference (cm)                  100.01±7.16              103.67±8.99            0.003
  ESS                                     7.39±4.27                7.24±4.01              0.789
  Total NREM sleep duration (min)         256.99±128.54            296.52±75.92           0.001
  Total REM sleep duration (min)          71.23±35.68              66.01±35.40            0.273
  Percentage of NREM sleep (%)            57.89±26.92              68.69±8.50             \<0.001
  Percentage of REM sleep (%)             16.02±7.30               15.25±7.63             0.432
  Total AHI                               17.27±16.81              22.88±19.46            0.015
  The longest apnea duration (sec)        29.99±20.33              27.79±16.39            0.334
  The longest hypopnea duration (sec)     47.19±21.05              49.53±18.86            0.399
  Average O~2~ saturation (%)             95.04±1.62               94.37±1.93             0.003
  Lowest O~2~ saturation (%)              85.20±5.76               83.52±6.56             0.033
  O~2~ desaturation index                 16.05±15.89              22.57±19.04            0.003
  Average HR                              62.63±9.88               62.31±9.58             0.806
  Glucose (mg/dL)                         108.53±29.05             116.85±46.43           0.165
  Cholesterol (mg/dL)                     177.43±40.19             180.71±42.33           0.544
  TG (mg/dL)                              129.53±89.19             150.24±100.85          0.050
  HDL (mg/dL)                             46.64±12.03              43.91±10.30            0.084
  LDL (mg/dL)                             106.55±36.61             102.24±35.10           0.259

BMI, body mass index; ESS, Epworth sleepiness scale; REM sleep, rapid eye movement sleep; NREM sleep, non rapid eye movement sleep; AHI, apnea-hypopnea index; HR, heart rate; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HTN, hypertension.

Data with normal distribution are presented as mean±standard deviation.

###### Univariate Logistic Regression Analysis of Risk Factors Associated with the Prevalence of OSA

![](ymj-56-1258-i004)

  Variables                                            Non-OSA (n=114)   OSA (n=361)      OR (95% CI)           *p* value
  ---------------------------------------------------- ----------------- ---------------- --------------------- -----------
  Age (yrs)                                            48.72±13.74       55.89±12.46      1.044 (1.026-1.062)   \<0.001
  Sex, male:female (percentage of male)                70:44 (60.5%)     280:81 (77.9%)   0.460 (0.293-0.722)   \<0.001
  Height (cm)                                          166.44±8.31       167.25±8.33      1.012 (0.986-1.037)   0.367
  Weight (kg)                                          70.66±12.59       75.33±12.65      1.032 (1.013-1.052)   \<0.001
  BMI (kg/m^2^)                                        25.31±3.48        26.70±3.41       1.140 (1.063-1.222)   \<0.001
  Neck circumference (cm)                              36.97±3.44        38.82±3.19       1.194 (1.114-1.280)   \<0.001
  Waist circumference (cm)                             89.84±10.23       95.17±8.48       1.073 (1.045-1.102)   \<0.001
  Hip circumference (cm)                               98.62±6.53        101.24±7.72      1.051 (1.019-1.083)   0.002
  Glucose (mg/dL)                                      104.62±27.92      111.77±33.78     1.009 (1.000-1.018)   0.056
  TG (mg/dL)                                           135.31±94.76      154.29±101.50    1.002 (1.000-1.005)   0.065
  HDL (mg/dL)                                          48.75±11.68       45.48±11.79      0.977 (0.961-0.995)   0.011
  LDL (mg/dL)                                          108.75±37.21      105.89±35.77     0.997 (0.991-1.003)   0.259
  Controlled:resistant (percentage of resistant HTN)   106:8 (7.0%)      304:57 (15.8%)   2.484 (1.148-5.378)   0.021

BMI, body mass index; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OSA, obstructive sleep apnea; HTN, hypertension; OR, odds ratio; CI, confidence interval.

Data with normal distribution are presented as mean±standard deviation.

###### Stepwise Logistic Regression Analysis of Risk Factors Associated with the Prevalence of OSA in Hypertensive Patients

![](ymj-56-1258-i005)

  Step   Stepwise selection (*p* value at entry or stay, \<0.25)   Multivariate model (c=0.767, AIC=448.79)                                   
  ------ --------------------------------------------------------- ------------------------------------------ --------- --------------------- ---------
  1      Waist circumference (cm)                                  28.82                                      \<0.001   1.056 (1.018-1.095)   0.003
  2      Age (yrs)                                                 35.01                                      \<0.001   1.067 (1.046-1.089)   \<0.001
  3      Male sex                                                  16.02                                      \<0.001   1.916 (0.959-3.829)   0.066
  4      Neck circumference (cm)                                   3.39                                       0.066     1.108 (0.979-1.255)   0.105
  5      Resistant HTN                                             1.62                                       0.203     1.708 (0.744-3.923)   0.207

OSA, obstructive sleep apnea; OR, odds ratio; CI, confidence interval; HTN, hypertension; AIC, Akaike Information Criterion.
